“Fenbendazole: Cheap Deworming Pill Shows Promise Against Drug-Resistant Lung Cancer” — what this page in the network covers. A common veterinary deworming medication, fenbendazole, may offer a new avenue for treating drug-resistant lung cancer, according to recent research highlighted by ScienceAlert. The study, which builds on earlier observations in animal models, suggests that this inexpensive and widely available drug can interfere with cancer cell metabolism and overcome resistance to standard therapies. Lung cancer remains a leading cause of cancer death worldwide, and resistance to drugs like paclitaxel and targeted therapies often limits treatment success.
Fenbendazole, already approved for animal use, has shown the ability to disrupt microtubule function and glucose uptake in cancer cells, effectively starving them and halting their growth. While human clinical trials are still needed, the low cost and established safety profile in animals make it an attractive candidate for repurposing. The full version stays on the original page, which this listing opens directly.